Monthly Archives: July 2018

Thrive is a supplemental training program for eStar that is specifically tailored for outpatient clinicians. The program was launched in June with a set of pilot sessions and has since been expanded to continue through the rest of the summer. Continue reading →

Lysyl oxidase like 2 (LOXL2) contributes to fibrogenesis by catalyzing cross linkage of collagen. We evaluated the safety and efficacy of simtuzumab, a monoclonal antibody against LOXL2, in a phase 2b trial of patients with advanced fibrosis caused by … Continue reading →

In 2017, the World Health Organization (WHO) designated clarithromycin-resistant Helicobacter pylori a high priority for antibiotic research and development. However, there are no clear data on the global distribution of resistance or its clinical effe… Continue reading →

As Congress and the Trump administration struggle with efforts to reform the US health care system, we thought it would be timely to update you on the work AGA does in Washington, DC, to support the science and practice of gastroenterology. Continue reading →

The incidence of inflammatory bowel diseases (IBD) is increasing globally, outpacing what genetic influences alone could instigate and implicating complex interactions with environmental factors including the gut microbiome in its elusive aetiology. We… Continue reading →

Faecalibacterium prausnitzii a member of the Clostridium IV group of the Firmicutes phylum that is abundant in the intestinal microbiota, has anti-inflammatory effects. The relative level of F prausnitzii is decreased in fecal samples from patients wit… Continue reading →

Screening patients with cirrhosis for hepatocellular carcinoma (HCC) has been recommended. We conducted a matched case–control study within the US Veterans Affairs (VA) healthcare system to determine whether screening by abdominal ultrasonography (US… Continue reading →

In 2 prospective cohorts, histologic grade of intestinal metaplasia before radiofrequency ablation for Barrett’s esophagus predicts recurrent neoplasia and can be used to determine surveillance intervals. Continue reading →

Recently, Li et al1 have reported that vein injection of nanoliposome C6-ceramide, a cell membrane permeable form of ceramide, slows growth of liver tumors in mice, through suppressing tumor-associated macrophage functions and enhancing tumor antigen-… Continue reading →